The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)

Completed · Not applicable · Has a placebo group

Conditions studied: Osteoporosis

In brief

The purpose of this study is to evaluate the effectiveness of once weekly risedronate in the prevention and treatment of bone loss in premenopausal and newly menopausal women with breast cancer who have received chemotherapy. The hypothesis is that bisphosphonate therapy will prevent bone loss at clinically relevant sites, such as the hip and spine. The investigators also hypothesize that there will be a correlation between biochemical markers of bone turnover and changes in bone mineral density.

Key facts

Study ID

NCT00118508

Run by

University of Pittsburgh

People needed

87

Starts

2003-05-01

Expected to finish

2006-07-01

Last updated by the study team

2015-08-13

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Pre- and newly postmenopausal (up to 8 years) women ages 18 and older
• Breast cancer treated with chemotherapeutic agents, with or without tamoxifen/aromatase inhibitors
• Negative pregnancy test

You may not qualify if…

• Stage 4 breast cancer
• Any illness or medications known to affect bone metabolism
• History of osteoporosis or history of vertebral or hip fractures
• Kidney stones in the past 5 years
• Active peptic ulcer disease

Where it is running

• University of Pittsburgh Medical Center (GCRC) — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.